These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3491964)

  • 21. Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP).
    Martinovits G; Melamed E; Cohen O; Rosenthal J; Uzzan A
    Neurosci Lett; 1986 Aug; 69(2):192-7. PubMed ID: 3489911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
    Behmand RA; Harik SI
    J Neurochem; 1992 Feb; 58(2):776-9. PubMed ID: 1445501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of dopamine uptake and cocaine binding in mouse striatum by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Sershen H; Reith ME; Hashim A; Lajtha A
    Eur J Pharmacol; 1984 Jun; 102(1):175-8. PubMed ID: 6332738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1-Methyl-4-cyclohexyl-1,2,3,6-tetrahydropyridine (MCTP): an alicyclic MPTP-like neurotoxin.
    Youngster SK; Saari WS; Heikkila RE
    Neurosci Lett; 1987 Aug; 79(1-2):151-6. PubMed ID: 3499585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contrasting tissue factors predict heterogeneous striatal dopamine neurotoxicity after MPTP or methamphetamine treatment.
    Marshall JF; Navarrete RJ
    Brain Res; 1990 Nov; 534(1-2):348-51. PubMed ID: 2073599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.
    Wiener HL; Hashim A; Lajtha A; Sershen H
    J Neurosci Res; 1989 Jul; 23(3):326-9. PubMed ID: 2504936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and toxicity toward nigrostriatal dopamine neurons of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) analogues.
    Fries DS; de Vries J; Hazelhoff B; Horn AS
    J Med Chem; 1986 Mar; 29(3):424-7. PubMed ID: 3485197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced dopamine D2 receptor hypersensitivity in the mouse is transient.
    Peroutka SJ; DeLanney L; Irwin I; Ison PJ; Ricaurte G; Schlegel JR; Langston JW
    Res Commun Chem Pathol Pharmacol; 1985 May; 48(2):163-71. PubMed ID: 3875136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity.
    Heikkila RE; Hess A; Duvoisin RC
    Life Sci; 1985 Jan; 36(3):231-6. PubMed ID: 3917525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice.
    Sonsalla PK; Heikkila RE
    Eur J Pharmacol; 1986 Oct; 129(3):339-45. PubMed ID: 3490988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversible serotoninergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse striatum studied by neurochemical and immunohistochemical approaches.
    Hara K; Tohyama I; Kimura H; Fukuda H; Nakamura S; Kameyama M
    Brain Res; 1987 May; 410(2):371-4. PubMed ID: 3297254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
    Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
    Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A high dose of MPTP overcomes the protective effect of selegiline against dopaminergic neurotoxicity.
    Fuller RW; Hemrick-Luecke SK
    J Pharm Pharmacol; 1989 Jul; 41(7):492-3. PubMed ID: 2570859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical evaluation of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons of young adult mice using dopamine and tyrosine hydroxylase antibodies.
    Mori S; Fujitake J; Kuno S; Sano Y
    Neurosci Lett; 1988 Jul; 90(1-2):57-62. PubMed ID: 2901058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic administration of nicotine fails to alter the MPTP-induced neurotoxicity in mice.
    Fung YK; Fiske LA; Lau YS
    Gen Pharmacol; 1991; 22(4):669-72. PubMed ID: 1936899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methamphetamine protects against MPTP neurotoxicity in C57BL mice.
    Sziráki I; Kardos V; Patthy M; Pátfalusi M; Budai G
    Eur J Pharmacol; 1994 Jan; 251(2-3):311-4. PubMed ID: 8149986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on striatal biopterin in BALB/c mice.
    Lee EH
    Neurosci Lett; 1988 Jun; 88(3):297-302. PubMed ID: 3260360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of serotonergic, corticostriatal and kainic acid lesions on the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in mice.
    Melamed E; Pikarski E; Goldberg A; Rosenthal J; Uzzan A; Conforti N
    Brain Res; 1986 Dec; 399(1):178-80. PubMed ID: 3492237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depletion of striatal dopamine by the N-oxide of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Lau YS; Fung YK; Trobough KL; Cashman JR; Wilson JA
    Neurotoxicology; 1991; 12(2):189-99. PubMed ID: 1956580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease.
    Sershen H; Hashim A; Lajtha A
    Pharmacol Biochem Behav; 1987 Oct; 28(2):299-303. PubMed ID: 3500479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.